Skip to content Skip to main menu

Pipelines

Our Microbiome Determines balanced health

Drug

※ MD Healthcare Inc Therapeutic pipelines (Core Indications: Cancer, Respiratory Disease, Central Nervous System (CNS) Disease, Metabolic Disease)

We are developing new therapeutic agents to treat various cancers such as lung cancer, colorectal cancer, and stomach cancer by analyzing extracellular vesicles secreted by microbe. And Based on the scientific evidence that the microbial extracellular vesicles are connected to the brain through the extracellular vesicles, and the fact that ir regulates our body's metabolic function, we are developing a treatment for diseases such as Alzheimer's dementia, autism, depression and metabolic diseases.

※ Advantages of microbial extracellular vesicle drugs

The microbial extracellular vesicle is a lipid bilayer membrane that packs proteins and various metabolites to selectively transfer substances to specific cells in a specific area. And proteins and metabolites contained in extracellular vesicles are transmitted to organelles within the cell, regulating metabolism and immune function to play a key role in cell homeostasis. Microbial extracellular vesicles have the advantage of being easily administered in oral or inhaled form, unlike exosomes and proteins, and can be easily mass-produced. In addition, unlike existing probiotics and products that use live bacteria, microbial extracellular vesicles do not multiply in our body, so side effects that occur in people with reduced immunity when living bacteria are administered can be avoided.

※What are Extracellular Vesicles?

Extracellular vesicles (EVs) are nanoparticles that transmit genetic information and cellular substances by wrapping DNA, proteins, and metabolites within spherical lipid bilayers. They are evolutionarily conserved mediators that exchange information and substances between cells. Extracellular vesicles play an important role in exchanging genes horizontally during evolution.

※Differences between microbial extracellular vesicles, live bacteria and human exosomes as innovative new drugs

Live Bacteria Human Cell Evs
(Exosomes)
Bacterial EVs
Efficacy
  • - Limited efficacy (Generally restricted to GI tract)
  • - Dependent on viability
  • - Targeting of distant organ (esp. brain) unfeasible
  • - Nanosized EVs circulate the body -> Target specific organ & certain EVs able to cross BBB
  • - Multimodal mode of action (MOA)
  • - Independent of viability
Safety
  • - Uncontrollable proliferation
  • - Potential for epigenetic modification
  • - Possible to control consistent conditions
  • - Low possibility to show toxicity
CMC
  • - Relatively low yield
  • - Storage & stability hurdles
  • - Low yield / High cost
  • - Relatively High yield / Low cost
  • - Minimal storage & stability issues

Pipeline

Relevant Research Publications

We have reported several studies showing that extracellular vesicles (EVs) secreted by pathogenic bacteria present in the environment are important factors in the pathogenesis of refractory diseases with immune function disorders such as respiratory diseases, cancer, skin diseases, and metabolic diseases. EVs secreted by beneficial bacteria that coexist with us are absorbed and distributed throughout our body and improve immunological homeostasis, which was first identified by suppressing disease outbreaks.

Immuno-Oncology

Respiratory Disease

CNS Disease